As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
COVID-19 and impact on peer review
The COVID-19 pandemic caused by severe acute respiratory syndrome SARS-CoV-2 infection has profoundly affected the lives of millions of people. Because the development of effective vaccines or novel drugs could take several months (if not years), repurposing existing drugs is considered a more efficient strategy that could save lives now. Statins constitute a class of lipid-lowering drugs with proven safety profiles and various known beneficial pleiotropic effects. Previous investigations have showed that statins have antiviral effects and are involved in the process of wound healing in the lung. This triggered researchers to evaluate if statin use reduces mortality in COVID-19 patients.
In the current retrospective study, Peymani and colleagues investigated whether statin use is associated with improved survival and clinical outcome in COVID-19 patients.
© enotmaks / Fotolia
Why publish with us
- Home for all valid research within pre-clinical and translational medicine
- Gold open access and compatible with growing funder mandates
- Specialised sections with expert Section Editors and Editorial Board
- Free access to all content, ensuring a wide dissemination of articles
- High website accesses with more than 18,900 page visits in the last 12 months
- Companion journal to Journal of Translational Medicine
Aims and scope
Translational Medicine Communications is an interdisciplinary forum for all scientifically valid research from across translational medicine. We publish research that focuses on the biology of disease, as well as preclinical and basic research that is closely associated with medicine. Translational Medicine Communications will also consider reviews, methodology articles, protocols and commentaries.
Our aim is to improve transparency and reproducibility within translational medicine, which is why we consider research papers regardless of outcome or significance of findings, as well as protocols for future research. We aim to serve the translational science community by publishing all scientifically valid and technically sound articles and we are dedicated to facilitating the communication between basic and clinical science.
Translational Medicine Communications is the companion journal to Journal of Translational Medicine.
Journal of Translational Medicine considers articles focusing on information derived from human experimentation to optimise the communication between basic and clinical science.
Editor-in-Chief: Francesco Marincola, Kite Pharma, USA
Dr. Marincola is Global Head of Research at Kite Pharma, Santa Monica, California. He was previously President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation; Chief Research Officer at Sidra Research, Qatar; and Tenured Investigator at the National Institutes of Health, Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine and is the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and the International Society for Translational Medicine. He edited several books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is also an award winning fiction author of The Wise Men of Pizzo and Cat Behind the Window.
Annual Journal Metrics
35 days to first decision for reviewed manuscripts only
29 days to first decision for all manuscripts
62 days from submission to acceptance
20 days from acceptance to publication